>> 全站文章索引 >> 第27页:
Effectiveness of Fluvoxamine and Paroxetine in Major Depressives with Psychotic Features - [EMILIO SACCHETTI 1 *, GIOVANNI CONTE 2, LAURA GUARNERI 3, ALESANDRO CALZERONI 2, MARA BERTINI 4, ADELAIDE PANARIELLO 4 AD:1Institute of Psychiatry, Second Chair Brescia University School of Medicine, Brescia, Italy2ASSL 39, University Department of Mental]
Selective serotonin reuptake inhibitors and withdrawal symptoms: a review of the literature - [Fran?ois Therrien 1, John S. Markowitz 2 * AD:1Faculté de Pharmacie, Université de Montréal, 2900, Boul. Edouard-Montpetit, C.P. 6128, succursale A, Montréal, Québec, Canada, H3C 3J72Department of Pharmacy Practice, Institute of Psychiatry, Medical U]
Setting New Standards for the Pharmacological Treatment of Panic Disorder - [R. KUMAR * AD:SmithKline Beecham Pharmaceuticals, New Frontiers Science Park (South), Third Avenue, Harlow, Essex CM19 5AW, UK]
Relationship between clinical effects, serum drug concentration, and concurrent drug interactions in depressed patients treated with citalopram, fluoxetine, clomipramine, paroxetine or venlafaxine - [C. Charlier 1 *, E. Pinto 2, M. Ansseau 2, G. Plomteux 1 AD:1University of Liège, Toxicology Laboratory, CHU Sart Tilman, B-4000 Liège, Belgium2University of Liège, Psychiatric Unit, CHU Sart Tilman, B-4000 Liège, Belgium]
A review of the safety of selective serotonin reuptake inhibitors during pregnancy - [David J. Goldstein 1 2 3 *, Karen Sundell 1 AD:1Neuroscience Division, Lilly Research Laboratories, Lilly Corporate Center-1730, Indianapolis, IN 46285, USA2Department of Pharmacology and Toxicology, Indiana University Medical School, Indianapolis, IN, US]
Treatment-emergent behavioural side effects with selective serotonin re-uptake inhibitors in adults with learning disabilities - [A. B. Biswas 1 *, S. Bhaumik 1, D. Branford 2 AD:1University of Leicester, & Leicestershire and Rutland Healthcare NHS Trust, Frith Hospital, Groby Road, Leicester LE3 9QF, UK2Southern Derbyshire Mental Health Trust, Kingsway Hospital, Derby DE22 3LZ, UK]
Tianeptine and paroxetine in major depressive disorder, with a special focus on the anxious component in depression: an international, 6-week double-blind study - [Jean Pierre Lepine 1 *, Carlo Altamura 2, Marc Ansseau 3, Jose Luis Ayuso Gutierrez 4, Istvan Bitter 5, Malcolm Lader 6, Lionel Waintraub 7 * AD:1Service de Psychiatrie, H魀ital Fernand Widal, 200, rue du Faubourg St Denis, 75745 Paris Cedex 10, France2Un]
Mirtazapine and paroxetine: a drug-drug interaction study in healthy subjects - [F. J. L. Ruwe 1, R. A. Smulders 3, H. J. Kleijn 2, H. L. A. Hartmans 3, J. M. A. Sitsen 1 * AD:1Clinical Development Department, NV Organon, PO Box 20, 5340 BH Oss, The Netherlands2Department of Drug Metabolism & Kinetics, NV Organon, PO Box 20, 5340 BH O]
Cytochrome P450 2D6 genotype does not predict SSRI (fluoxetine or paroxetine) induced hyponatraemia - [Catherine A. M. Stedman 1, Evan J. Begg 1 *, Martin A. Kennedy 2, Rebecca Roberts 2, Timothy J. Wilkinson 3 AD:1Department of Clinical Pharmacology, Christchurch Hospital, Christchurch School of Medicine, Christchurch, New Zealand2Department of Pathology,]
Seasonal variations in the binding of [3H]paroxetine to the platelet serotonin transporter sites in African-American cocaine-dependent patients and healthy volunteers - [Ashwin A. Patkar 1 *, Wade H. Berrettini 2, Allan Lundy 1, Heather W. Murray 1, Kevin P. Hill 1, Michael J. Vergare 1, Stephen P. Weinstein 1 AD:1Division of Substance Abuse Programs, Department of Psychiatry and Human Behavior, Thomas Jefferson Universit]
Use of paroxetine for the treatment of depression and anxiety disorders in the elderly: a review - [Michel Bourin 1 2 * AD:1Neurobiology of Anxiety and Depression, Faculty of Medicine, Nantes, France2Neurochemical Research Unit, University of Alberta, Edmonton, Alberta, Canada]
A placebo controlled investigation into the effects of paroxetine and mirtazapine on measures related to car driving performance - [F. Ridout *, R. Meadows, S. Johnsen, I. Hindmarch AD:HPRU Medical Research Centre, University of Surrey, Egerton Road, Guildford GU2 7XP, UK]
Differential period of onset of action of fluvoxamine, paroxetine and milnacipran for depression - [Shigeru Morishita 1 *, Seizaburo Arita 2 AD:1Department of Psychiatry, Kawasaki Medical School, Kurashiki, Okayama, Japan2Department of Mathematics, Kansai Medical School, Hirakata, Osaka, Japan]
Induction of mania in depression by paroxetine - [Shigeru Morishita 1 *, Seizaburo Arita 2 AD:1Department of Psychiatry, Kawasaki Medical School, Kurashiki, Okayama, Japan2Department of Mathematics, Kansai Medical School, Hirakata, Osaka, Japan]
Paroxetine in the treatment of depressed patients with haematological malignancy: an open-label study - [Chi-Un Pae 1, Yoo-Jin Kim 2, Wang-Youn Won 1, Hee-Je Kim 2, Seok Lee 2, Chang-Uk Lee 1, Soo-Jung Lee 1, Dong-Wook Kim 2, Chul Lee 1 *, Woo-Sung Min 2, Chun-Choo Kim 2, In-Ho Paik 1, Alessandro Serretti 3 AD:1Department of Psychiatry, Kangnam St Mary]
Comorbid cannabis use and panic disorder: short term and long term follow-up study - [Pinhas N. Dannon 1 2 3 *, Katherine Lowengrub 1 3, Revital Amiaz 2, Leon Grunhaus 2, Moshe Kotler 3 AD:1Rehovot Community Mental Health Care and Rehabilitation Centre, Israel2Chaim Sheba Med Centre, Psychiatry Ward, Tel Hashomer, Israel3Beer Ya]
Paroxetine treatment of delusional disorder, somatic type - [Hiroshi Hayashi, Shingo Oshino, Junichi Ishikawa, Shinobu Kawakatsu, Koichi Otani * AD:Department of Neuropsychiatry, Yamagata University School of Medicine, 2-2-2 Iidanishi, Yamagata 990-9585, Japan]
Serum disposition of sertraline, N-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression - [Margareta Reis 1 2 *, Anna ?berg-Wistedt 3, Hans ?gren 4, Peter H?glund 2, Ann-Charlotte ?kerblad 5, Finn Bengtsson 5 AD:1Department of Medicine and Care, Division of Clinical Pharmacology, Faculty of Health Sciences, Link?ping University, Link?ping, Swed]
Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine - [Christer Allgulander 1 *, Richard Mangano 2, Jun Zhang 2, Alv A. Dahl 3, Ulla Lepola 4, Ingemar Sj?din 5, Gerard Emilien 6, for the SAD 388 Study Group AD:1Karolinska Institutet, The Neurotec Department, Section of Psychiatry, Stockholm, Sweden2Wyeth Rese]
Differential effects of fluvoxamine, paroxetine and milnacipran for depression, especially with regard to age - [Shigeru Morishita 1 2 *, Seizaburo Arita 2 AD:1Depression Prevention Medical Center, Kyoto Jujo Hospital, Kyoto, Japan2Department of Mathematics, Kansai Medical School, Hirakata, Osaka, Japan]
Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine - [P. Vandel 1, D. Sechter 1, E. Weiller 2, N. Pezous 2, F. Cabanac 2, A. Tournoux 2, E. Panconi 2 AD:1Service de Psychiatrie et Psychologie Médicale, CHU St Jacques, Besan?on, France2Institut De Recherche Pierre Fabre, Boulogne, France]
A Formal Synthesis of (-)-Paroxetine by Enantioselective Ring Enlargement of a Trisubstituted Prolinol - [Janine Cossy 1 *, Olivier Mirguet 1, Domingo Gomez Pardo 1 *, Jean-Roger Desmurs 2 AD:1Laboratoire de Chimie Organique associé au CNRS, ESPCI, 10 rue Vauquelin, 75231 Paris Cedex 05, France, Fax: (internat.) + 33-(0)1407946602Rhodia, 190 avenue Thiers, 6]
A Convenient Synthesis of (-)-Paroxetine - [László Czibula 1, András Nemes 1 *, Ferenc Seb?k 1, Csaba Szántay Jr. 2, Marianna Mák 2 AD:1Chemical Works of Gedeon Richter Ltd., Technological Research Laboratory No. I., P. O. Box 27, 1475 Budapest 10, Hungary2Chemical Works of Gedeon Richter Ltd.]
Development and validation method for determination of Paroxetine and its metabolites by nonaqueous capillary electrophoresis in human urine. Experimental design for evaluating the ruggedness of the method - [Juana Rodríguez Flores *, Juan J. Barzas Nevado, Ana M. Contento Salcedo, Maria P. Cabello Díaz AD:Department of Analytical Chemistry and Foods Technology, Ciudad Real, Spain]
Medication treatments for panic disorder and social phobia - [Murray B. Stein, M.D. * AD: Department of Psychiatry, University of California, San Diego, La Jolla, California]
Accelerating response in geriatric depression: A pilot study combining sleep deprivation and paroxetine - [Gregory M. Bump, M.S. 1, Charles F. Reynolds III, M.D. 1 *, Gwenn Smith, Ph.D. 1, Bruce G. Pollock, M.D., Ph.D. 1, Mary Amanda Dew, Ph.D. 1, Sati Mazumdar, Ph.D. 1, Matthew Geary, B.A. 1, Patricia R. Houck, M.S.H. 1, David J. Kupfer, M.D. 2 AD:1Mental Hea]
Managing rapid metabolizers of antidepressants - [Robert P. Kraus, F.R.C.P.C. *, Paula Diaz, B.Sc. (Hons), M.R. Pharm. S., L.H.S.C., Andrea McEachran, B.A. (Hons), L.H.S.C. AD:Department of Psychiatry, London Health Sciences Centre, Victoria Campus, London, Ontario, Canada]
SSRIs in the Treatment of obsessive-compulsive disorder - [Charles Cartwright, M.D., Eric Hollander, M.D. * AD:Mount Sinai School of Medicine, New York, New York]
Social anxiety disorder under scrutiny - [Jonathan R.T. Davidson, M.D. * AD:Department of Psychiatry and Behavioral Science, Duke University Medical Center, Durham, North Carolina]
Therapeutic advances: Paroxetine for the treatment of social anxiety disorder - [R. Bruce Lydiard, Ph.D., M.D. 1 *, Julio Bobes 2 AD:1Department of Psychiatry, Medical University of South Carolina, Charleston, South Carolina2Facultad de Medicina, Universidad de Oviedo, Spain]
Effects of nortriptyline and paroxetine on QT variability in patients with panic disorder - [Vikram K. Yeragani, M.B.B.S. 1 2 3 *, Robert Pohl, M.D. 1, V.C. Jampala, M.B.B.S. 2, Richard Balon, M.D. 1, C. Ramesh, M.D. 1, K. Srinivasan, M.D. 4 AD:1Department of Psychiatry, Wayne State University School of Medicine, Detroit, Michigan2Veterans Affair]
Paroxetine versus nortriptyline in the continuation and maintenance treatment of depression in the elderly - [Gregory M. Bump, M.D., Benoit H. Mulsant, M.D., Bruce G. Pollock, M.D., Ph.D., Sati Mazumdar, Ph.D., Amy E. Begley, M.A., Mary Amanda Dew, Ph.D., Charles F. Reynolds III, M.D. * AD:Intervention Research Center for Late-Life Mood Disorders, Department of P]
Paroxetine for social anxiety and alcohol use in dual-diagnosed patients - [Carrie L. Randall, Ph.D. 1 *, Michael R. Johnson, M.D. 1, Angelica K. Thevos, Ph.D. 1, Susan C. Sonne, Pharm.D. 1, Suzanne E. Thomas, Ph.D. 1, Shauna L. Willard, M.A. 1, Kathleen T. Brady, M.D., Ph.D. 1, Jonathan R. Davidson, M.D. 2 AD:1Alcohol Research C]
Citalopram treatment of paroxetine-intolerant depressed patients - [Michael E. Thase, M.D. 1 *, James M. Ferguson, M.D. 2, R. Bruce Lydiard, M.D., Ph.D. 3, Charles S. Wilcox, Ph.D. 4 AD:1Department of Psychiatry University of Pittsburgh School of Medicine, Western Psychiatric Institute Clinic, Pittsburgh, Pennsylvania2Pha]
The effect of alexithymic features on response to antidepressant medication in patients with major depression - [Aytekin ?zsahin, M.D., ?zcan Uzun, M.D. *, Adnan Cansever, M.D., Zeynep Gulcat, Ph.D. AD:Department of Psychiatry, Gulhane School of Medicine, Ankara, Turkey]
Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: Randomised, double-blind, placebo-controlled, fixed-dose study - [Malcolm Lader, M.D. 1 *, Karina Stender, Ph.D. 2, Vera Bürger, M.Sc. 3, Rico Nil, Ph.D. 4 AD:1Institute of Psychiatry, University of London, London, United Kingdom2H. Lundbeck A/S, Copenhagen, Denmark3Lundbeck Austria GmbH, Vienna, Austria4Lundbeck (Swit]
An open trial of paroxetine for the offensive subtype of taijin kyofusho and social anxiety disorder - [Toshihiko Nagata, M.D., Ph.D. 1 *, Irene van Vliet, M.D. 2, Hisashi Yamada, M.D. 1, Kouhei Kataoka, M.D. 1, Toshiya Iketani, M.D., Ph.D. 1, Nobuo Kiriike, M.D., Ph.D. 1 1Department of Neuropsychiatry, Osaka City University Medical School, Osaka, Japan2Dep]
A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder - [Mark H. Pollack, M.D. 1 *, Ulla Lepola, M.D. 2, Hannu Koponen, M.D. 3, Naomi M. Simon, M.D. 1, John J. Worthington, M.D. 1, Gerard Emilien, Ph.D. 4, Evan Tzanis, B.A. 5, Eliseo Salinas, M.D. 5, Timothy Whitaker, M.D. 5, Bo Gao, Ph.D. 5 AD:1Massachusetts G]
A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults - [Randall D. Marshall, M.D. *, Roberto Lewis-Fernandez, M.D., Carlos Blanco, M.D., Ph.D., H. Blair Simpson, M.D., Ph.D., Shu-Hsing Lin, Ph.D., Donna Vermes, M.S.N.P.P., Wendy Garcia, B.A., Franklin Schneier, M.D., Yuval Neria, Ph.D., Arturo Sanchez-Lacay, M]
Paroxetine retards disease onset and progression in Huntingtin mutant mice - [Wenzhen Duan, MD, PhD 1 *, Zhihong Guo, MD 1, Haiyang Jiang, MD 1, Bruce Ladenheim, MS 2, Xiangru Xu, PhD 1, Jean Lud Cadet, MD 2, Mark P. Mattson, PhD 1 3 AD:1Laboratory of Neurosciences, National Institute on Aging Intramural Research Program2Molecular]
Serotonin in Aging, Late-Life Depression, and Alzheimer's Disease: The Emerging Role of Functional Imaging - [Carolyn Cidis Meltzer MD, Gwenn Smith Ph.D, Steven T DeKosky MD, Bruce G Pollock MD, Ph.D, Chester A Mathis Ph.D, Robert Y Moore MD, Ph.D, David J Kupfer MD and Charles F Reynolds III MD]
Presence and Characterization of the Serotonin Transporter in Human Resting Lymphocytes - [Donatella Marazziti MD, Alessandra Rossi Dr Biol.Sci, Gino Giannaccini Dr Biol.Sci, Stefano Baroni Dr Biol.Sci, Antonio Lucacchini Dr Biol.Sci and Giovanni B Cassano MD, FRCP]
Aggression, Impulsivity, and Central Nervous System Serotonergic Responsivity in a Nonpatient Sample - [Stephen B Manuck1 Ph.D, Janine D Flory1 Ph.D, Jeanne M McCaffery1 BA, Karen A Matthews3 Ph.D, J John Mann4 MD and Matthew F Muldoon2 MD, MPH]
Characterization of the Translocation of Protein Kinase C (PKC) by 3,4-methylenedioxymethamphetamine (MDMA/Ecstasy) in Synaptosomes: Evidence for a Presynaptic Localization Involving the Serotonin Transporter (SERT) - [H Kenneth Kramer1 MD, Ph.D, Jose C Poblete2 Ph.D and Efrain C Azmitia2 Ph.D]
Subchronic Administration of Fluoxetine Impairs Estrous Behavior in Intact Female Rats - [Josefa Vega Matuszczyk1 Ph.D, Knut Larsson1 Ph.D and Elias Eriksson2 Ph.D]
Decreased Neuroendocrine Responses to Meta-Chlorophenylpiperazine (m-CPP) but Normal Responses to Ipsapirone in Marathon Runners - [Andreas Broocks1 MD, Tim Meyer5 MD, Annette George2 MD, Ursula Hillmer-Vogel4 MD, Detlef Meyer1 MD, Borwin Bandelow1 MD, G?ran Hajak1 MD, Uwe Bartmann1 Ph.D, Christoph H Gleiter3 MD and Eckart Rüther1 MD]
Serotonergic and Noradrenergic Markers of Post-Traumatic Stress Disorder with and without Major Depression - [Michael Maes1,2,3 MD, Ph.D, Ai-hua Lin1 MD, MSci, Robert Verkerk4 Ing, Laure Delmeire1 MD, An Van Gastel MD, Marc Van der Planken5 MD, Ph.D and Simon Scharpé4 Ph.D]
Plasma Anti-Serotonin and Serotonin Anti-Idiotypic Antibodies Are Elevated in Panic Disorder - [Jeremy D Coplan MD, Hadassah Tamir Ph.D, Denise Calaprice Ph.D, MaryBeth DeJesus BA, Manuel De La Nuez BA, Daniel Pine MD, Laszlo A Papp MD, Donald F Klein MD and Jack M Gorman MD]
Effects of Fluoxetine on the Polysomnogram in Outpatients with Major Depression - [Madhukar H Trivedi1 MD, A John Rush1 MD, Roseanne Armitage1 Ph.D, Christina M Gullion1 Ph.D, Bruce D Grannemann1 MA, Paul J Orsulak1 Ph.D and Howard P Roffwarg2 MD]
O- and N-demethylation of Venlafaxine In Vitro by Human Liver Microsomes and by Microsomes from cDNA-Transfected Cells: Effect of Metabolic Inhibitors and SSRI Antidepressants - [Steven M Fogelman, Jürgen Schmider, Karthik Venkatakrishnan, Lisa L von Moltke, Jerold S Harmatz, Richard I Shader and David J Greenblatt]
5-HT1A Receptor Function in Normal Subjects on Clinical Doses of Fluoxetine: Blunted Temperature and Hormone Responses to Ipsapirone Challenge - [Bernard Lerer1 MD, Yevgenia Gelfin1 MD, Malka Gorfine2 MA, Bruno Allolio3 MD, K Peter Lesch4 MD and Michael E Newman1 Ph.D]
Ionic interactions in the Drosophila serotonin transporter identify it as a serotonin channel - [Christina I. Petersen, Louis J. DeFelice]
Serotonin and Drug-Induced Therapeutic Responses in Major Depression, Obsessive-Compulsive and Panic Disorders - [Pierre Blier MD, Ph.D and Claude de Montigny MD, Ph.D]
Effects of Repeated High-Dose Methamphetamine on Local Cerebral Glucose Utilization in Rats - [Yn-Ho Huang1 Ph.D, Shih-Jen Tsai2,3 MD, Ting-Wen Su1 MSc and Cho-Boon Sim2 MD]
Is A Single Dose of MDMA Harmless - [Franz X Vollenweider, Alex Gamma, Matthias Liechti, Theo Huber]
Comparison of the Novel Antipsychotic Ziprasidone with Clozapine and Olanzapine: Inhibition of Dorsal Raphe Cell Firing and the Role of 5-HT1A Receptor Activation - [Jeffrey S Sprouse Ph.D, Linda S Reynolds MS, John P Braselton BS, Hans Rollema Ph.D and Stevin H Zorn Ph.D]
Auditory Evoked Potentials Reflect Serotonergic Neuronal Activity?A Study in Behaving Cats Administered Drugs Acting on 5-HT1A Autoreceptors in the Dorsal Raphe Nucleus - [Georg Juckel1 MD, Ulrich Hegerl1 MD, Ph.D, Márk Molnár2 MD, Ph.D, Valéria Csépe2 Ph.D and George Karmos2 MD, Ph.D]
Localized Orbitofrontal and Subcortical Metabolic Changes and Predictors of Response to Paroxetine Treatment in Obsessive-Compulsive Disorder - [Sanjaya Saxena1 MD, Arthur L Brody1 MD, Karron M Maidment1 RN, Jennifer J Dunkin1 Ph.D, Mark Colgan2 ME, Shervin Alborzian2, Michael E Phelps2 Ph.D and Lewis R Baxter Jr1,2,3 MD]
Serotonin Reuptake Inhibition by Citalopram in Rat Strains Differing for Their Emotionality - [Fabrice Pollier1 MS, Sophie Sarre2 Ph.D, Sylvie Aguerre1 AS, Guy Ebinger3 MD, Pierre Mormède1 Ph.D, Yvette Michotte2 Ph.D and Francis Chaouloff1 Ph.D]
Strain Differences in the Behavioral Effects of Antidepressant Drugs in the Rat Forced Swimming Test - [Carolina López-Rubalcava Ph.D and Irwin Lucki Ph.D]
Multiple 5-HT Receptors in Passive Avoidance: Comparative Studies of p-Chloroamphetamine and 8-OH-DPAT - [Ilga Misane Ph.D, Sven Ove ?gren and Med Sc]
Peripheral Markers of Serotonergic and Noradrenergic Function in Post-Pubertal, Caucasian Males with Autistic Disorder - [Jan Croonenberghs1 MD, Laure Delmeire2 MD, Robert Verkerk3 Ph.D, Ai-hua Lin2,3 MD, MSci, Anisa Meskal5 Ph.D, Hugo Neels5 Ph.D, Marc Van der Planken6 MD, Ph.D, Simon Scharpe3 Ph.D, Dirk Deboutte1 MD, Ph.D, Greet Pison4 Ph.D and Michael Maes2,7,8,9 MD, Ph.D]
Increased Tonic Activation of Rat Forebrain 5-HT1A Receptors by Lithium Addition to Antidepressant Treatments - [Nasser Haddjeri Ph.D, Steven T Szabo BSc, Claude de Montigny MD, Ph.D and Pierre Blier MD, Ph.D]
Possible association of the short allele of the serotonin transporter promoter gene polymorphism (5-HTTLPR) with violent suicide - [B Bondy1, A Erfurth1, S de Jonge1, M Krüger1 and H Meyer2]
Mice lacking the norepinephrine transporter are supersensitive to psychostimulants - [Fei Xu, Raul R. Gainetdinov, William C. Wetsel, Sara R. Jones, Laura M. Bohn, Gary W. Miller, Yan-Min Wang, Marc G. Caron]
Neurotransmitter transporters: fruitful targets for CNS drug discovery - [L Iversen]
Potentiation by (-)Pindolol of the Activation of Postsynaptic 5-HT1A Receptors Induced by Venlafaxine - [Jean-Claude Bé?que Ph.D, Pierre Blier MD, Ph.D, Claude de Montigny MD, Ph.D and Guy Debonnel MD]
The Corticosteroid Receptor Hypothesis of Depression - [Florian Holsboer MD, Ph.D]
Allelic Variation in the Serotonin Transporter Promoter Affects Onset of Paroxetine Treatment Response in Late-Life Depression - [Bruce G Pollock1 MD, Ph.D, Robert E Ferrell3 Ph.D, Benoit H Mulsant1 MD, Sati Mazumdar4 Ph.D, Mark Miller2 MD, Robert A Sweet1 MD, Stephanie Davis1 MEd, Margaret A Kirshner1 BA, Patricia R Houck2 MS, Jacqueline A Stack2 MSN, Charles F Reynolds III2 MD and]
In Vivo Measurement of the Vesicular Monoamine Transporter in Schizophrenia - [Stephan F Taylor1 MD, Robert A Koeppe2 Ph.D, Rajiv Tandon1 MD, Jon-Kar Zubieta1,4 MD, Ph.D and Kirk A Frey2,3,4 MD, Ph.D]
Clinical and Physiological Consequences of Rapid Tryptophan Depletion - [.]
Modifications in Brain CaM Kinase II after Long-Term Treatment with Desmethylimipramine - [E Consogno2 Ph.D, G Racagni1,2 Ph.D and M Popoli1,3 Ph.D]
Genomic organization of the SLC1A1/EAAC1 gene and mutation screening in early-onset obsessive-compulsive disorder - [J Veenstra-VanderWeele1, S-J Kim1, D Gonen1, G L Hanna2, B L Leventhal1,3 and E H Cook Jr1,3]
Extrapyramidal symptoms and antidepressant drugs: neuropharmacological aspects of a frequent interaction in the elderly - [S Govoni1, M Racchi1, E Masoero1, M Zamboni2 and L Ferini-Strambi2]
Differential Occupancy of Somatodendritic and Postsynaptic 5HT1A Receptors by Pindolol: A Dose-Occupancy Study with [11C]WAY 100635 and Positron Emission Tomography in Humans - [Diana Martinez1 MD, Dah-Ren Hwang1 Ph.D, Osama Mawlawi1 Ph.D, Mark Slifstein1 Ph.D, Justine Kent1 MD, Norman Simpson1 BS, Ramin V Parsey1 MD, Ph.D, Tomoki Hashimoto1 MD, Yiyun Huang1 Ph.D, Ann Shinn1 BS, Ronald Van Heertum1 MD, Anissa Abi-Dargham1 MD, Ste]
Association between violent suicidal behavior and the low activity allele of the serotonin transporter gene - [P Courtet1, P Baud2, M Abbar3, J P Boulenger4, D Castelnau1, D Mouthon2, A Malafosse2 and C Buresi2]
Local 5,7-Dihydroxytryptamine Lesions of Rat Amygdala: Release of Punished Drinking, Unaffected Plus-Maze Behavior and Ethanol Consumption - [Wolfgang Sommer1 MD, Ph.D, Christian Moller1 MD, Ph.D, Lisa Wiklund1 BSc, Annika Thorsell1 Ph.D, Roberto Rimondini1 Ph.D, Hans Nissbrandt2 MD, Ph.D and Markus Heilig1 MD, Ph.D]
Social Impulsivity Inversely Associated with CSF 5-HIAA and Fluoxetine Exposure in Vervet Monkeys - [Lynn A Fairbanks1 Ph.D, William P Melega1,2 Ph.D, Matthew J Jorgensen1 Ph.D, Jay R Kaplan3 Ph.D and Michael T McGuire1,4 MD]
Role of 5-HT1A and 5-HT1B Receptors in the Mediation of Behavior in the Forced Swim Test in Mice - [Michael F O'Neill Ph.D and Michael W Conway]
The Serotonin Reuptake Inhibitor Fluoxetine Reduces Sex Steroid-Related Aggression in Female Rats: An Animal Model of Premenstrual Irritability? - [Hoi-Por Ho MS, Marie Olsson, M Pharm, Lars Westberg BS, Jonas Melke MS and Elias Eriksson Ph.D]
Effects of Antidepressant Drugs on the Behavioral and Physiological Responses to Lipopolysaccharide (LPS) in Rodents - [Raz Yirmiya1 Ph.D, Yehuda Pollak1 MA, Ohr Barak1 MA, Ronit Avitsur1 Ph.D, Haim Ovadia2 Ph.D, Michael Bette3 Ph.D, Eberhard Weihe3 MD and Joseph Weidenfeld2 Ph.D]
Assessment of the Serotonin and Norepinephrine Reuptake Blocking Properties of Duloxetine in Healthy Subjects - [Julie E Turcotte MD, Guy Debonnel MD, Claude de Montigny MD, Ph.D, Chantal Hébert RN and Pierre Blier MD, Ph.D]
1-(m-Chlorophenyl)piperazine (mCPP) Dissociates In Vivo Serotonin Release from Long-Term Serotonin Depletion in Rat Brain - [Michael H Baumann Ph.D, Mario A Ayestas BS, Christina M Dersch MS and Richard B Rothman MD, Ph.D]
Effects of Sodium Valproate on Corticotropin-Releasing Factor Systems in Rat Brain - [Steven C Stout Ph.D, Michael J Owens Ph.D, Kimberly P Lindsey BS, David L Knight BS and Charles B Nemeroff MD, Ph.D]
Chronic Effects of Triiodothyronine in Combination with Imipramine on 5-HT Transporter, 5-HT1A and 5-HT2A Receptors in Adult Rat Brain - [X Moreau Ph.D, R Jeanningros Ph.D and P Mazzola-Pomietto Ph.D]
Response in Relation to Baseline Anxiety Levels in Major Depressive Disorder Treated with Bupropion Sustained Release or Sertraline - [A John Rush1 MD, Madhukar H Trivedi1 MD, Thomas J Carmody2 Ph.D, Rafe M J Donahue3 Ph.D, Trisha L Houser3 BA, Carolyn Bolden-Watson3 Ph.D, Sharyn R Batey4 Pharm.D, John A Ascher4 MD and Alan Metz3 MDD:1Department of Psychiatry, University of Texas Southwe]
The Effect of Tryptophan on Social Interaction in Everyday Life: A Placebo-Controlled Study - [DS Moskowitz1 Ph.D, Gilbert Pinard2 MD, David C Zuroff1 Ph.D, Lawrence Annable2 BSc, Dip Stat and Simon N Young2 Ph.D]
Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity - [A Serretti, R Zanardi, D Rossini, C Cusin, R Lilli and E Smeraldi]
Serotonin-Dopamine Interactions in the Control of Conditioned Reinforcement and Motor Behavior - [Deanna M Sasaki-Adams BS and Ann E Kelley Ph.D]
Prolactin Response to dl-Fenfluramine Challenge before and after Treatment with Paroxetine - [Michael C Dulchin MD, Maria A Oquendo MD, Kevin M Malone MD, Steven P Ellis Ph.D, Shuhua Li Ph.D and J John Mann MD]
The pharmacogenomics of depression - [J Licinio, M-L Wong]
Vagus Nerve Stimulation (VNS?) for Treatment-Resistant Depression: Efficacy, Side Effects, and Predictors of Outcome - [Harold A Sackeim1,2,3 Ph.D, A John Rush5 MD, Mark S George7,8,10 MD, Lauren B Marangell11 MD, Mustafa M Husain5 MD, Ziad Nahas7 MD, Christopher R Johnson11 MD, Stuart Seidman1,2 MD, Cole Giller6 MD, Stephen Haines9 MD, Richard K Simpson Jr12 MD and Robert]
Clinical Neurochemical Implications of Sleep Deprivation's Effects on the Anterior Cingulate of Depressed Responders - [Joseph C Wu1 MD, Monte Buchsbaum2 MD and William E Bunney Jr1 MD]
Effects of Endogenous Neurotransmitters on the in vivo Binding of Dopamine and 5-HT Radiotracers in Mice - [Onarae V Rice1 MA, S John Gatley1 Ph.D, Ji Shen1 Ph.D, Craig L Huemmer1 BS, Renata Rogoz1 Ph.D, Onofre T DeJesus2 Ph.D, Nora D Volkow1 MD and Andrew N Gifford1 Ph.D]
Serotonin 1A Receptors, Serotonin Transporter Binding and Serotonin Transporter mRNA Expression in the Brainstem of Depressed Suicide Victims - [Victoria Arango1,2,3 Ph.D, Mark D Underwood1,2 Ph.D, Maura Boldrini1,2 MD, Hadassah Tamir1,2,3 Ph.D, Suham A Kassir1 BA, Shu-chi Hsiung1 MS, Jason J-X Chen3 MD, Ph.D and J John Mann1,2 MD]
Effects of Standardized Extracts of St. John's Wort on the Single-Unit Activity of Serotonergic Dorsal Raphe Neurons in Awake Cats: Comparisons with Fluoxetine and Sertraline - [Casimir A Fornal Ph.D, Christine W Metzler MS, Christian Mirescu BS, Susan K Stein MS and Barry L Jacobs Ph.D]
Effects of Standardized Extracts of St. John’s Wort on the Single-Unit Activity of Serotonergic Dorsal Raphe Neurons in Awake Cats: Comparisons with Fluoxetine and Sertraline - [Steven T Szabo1 BSc and Pierre Blier2 MD, Ph.D]
Vasopressin Mediates the Response of the Combined Dexamethasone/CRH Test in Hyper-anxious Rats: Implications for Pathogenesis of Affective Disorders - [Martin E Keck MD, Alexandra Wigger Ph.D, Tobias Welt BSc, Marianne B Muller MD, Angela Gesing Ph.D, Johannes M H M Reul Ph.D, Florian Holsboer MD, Ph.D, Rainer Landgraf Ph.D and Inga D Neumann Ph.D]
NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D2 and serotonin 5-HT2receptors-implications for models of schizophrenia - [S Kapur1 and P Seeman1,2]
5-HT2A promoter polymorphism -1438G/A in children and adolescents with obsessive-compulsive disorders - [S Walitza1, C Wewetzer1, A Warnke1, M Gerlach1, F Geller5, G Gerber2, T G?rg5, B Herpertz-Dahlmann3, E Schulz4, H Remschmidt2, J Hebebrand2 and A Hinney2]
分页: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 [27] 28 29 30 31 32 33 34 35 36 37 38 39 40
41 42 43 44 45 46 47 48 49 50 |